Corcept Therapeutics Inc.
- CORT · Nasdaq
- Pharmaceutical Preparations
- Redwood City, CA
- 730 employees
- CIK 0001088856
Updated from SEC filings through
Top things to know
Executives
-
Joseph K. Belanoff MD, Corcept’s Chief Executive Officer 8-K, 2026-11-03 -
Atabak Mokari Chief Financial Officer 4, 2026-09-03 - Bill Guyer PharmD, Corcept’s Chief Development Officer 8-K, 2026-11-03
- Gary Charles Robb Chief Business Officer 4, 2026-09-28
- Roberto Wandenkolk Vieira President, Oncology 4, 2026-09-18
- William Guyer Chief Development Officer 4, 2026-09-03
What leadership is saying
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business”
Earnings press release (8-K Ex. 99.1), filed November 3, 2026
Corcept Therapeutics Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Redwood City, CA. It trades as CORT on Nasdaq. Revenue was $761M in the fiscal year ending December 31, 2025, +12.8% from the year before. It reported about 730 employees. Joseph K. Belanoff is MD, Corcept’s Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $761M 10-K, 2026-02-24 | $675M 10-K, 2026-02-24 | $482M 10-K, 2026-02-24 | $402M 10-K, 2025-02-26 | $366M 10-K, 2024-02-15 |
| Operating income | $44.8M 10-K, 2026-02-24 | $137M 10-K, 2026-02-24 | $107M 10-K, 2026-02-24 | $113M 10-K, 2025-02-26 | $124M 10-K, 2024-02-15 |
| SG&A | $449M 10-K, 2026-02-24 | $280M 10-K, 2026-02-24 | $184M 10-K, 2026-02-24 | $153M 10-K, 2025-02-26 | $122M 10-K, 2024-02-15 |
| Net income | $99.7M 10-K, 2026-02-24 | $141M 10-K, 2026-02-24 | $106M 10-K, 2026-02-24 | $101M 10-K, 2025-02-26 | $113M 10-K, 2024-02-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Joseph K. Belanoff Chief Executive Officer at Corcept Therapeutics | MD, Corcept’s Chief Executive Officer | 8-K, 2026-11-03 |
| Atabak Mokari | Chief Financial Officer | 4, 2026-09-03 |
| Joshua M. Murray | Board member (per proxy) bio: Chief Financial Officer and Head of Strategy of Orca Bio | DEF 14A, 2026-04-17 |
| Bill Guyer | PharmD, Corcept’s Chief Development Officer | 8-K, 2026-11-03 |
| Gary Charles Robb | Chief Business Officer | 4, 2026-09-28 |
| Roberto Wandenkolk Vieira | President, Oncology | 4, 2026-09-18 |
| William Guyer | Chief Development Officer | 4, 2026-09-03 |
 Charles Robb | Named in proxy bio: Chief Business Officer and Secretary | DEF 14A, 2026-04-17 |
| Sean Maduck | President, Corcept Endocrinology | DEF 14A, 2026-04-17 |
| Daniel N. Swisher, Jr. | Board member (per proxy) bio: Former President and Chief Operating Officer of Jazz Pharmaceuticals | DEF 14A, 2026-04-17 |
| Joseph D. Lyon | Named in proxy bio: Chief Accounting and Technology Officer | DEF 14A, 2026-04-17 |
| Kimberly Park | Board member (per proxy) bio: Former Global Vice President of Merck & Co. | DEF 14A, 2026-04-17 |
| William Guyer, Pharm.D. | Named in proxy bio: Chief Development Officer | DEF 14A, 2026-04-17 |
| Hazel Hunt Chief Scientific Officer at Corcept Therapeutics | Chief Scientific Officer | 4, 2026-03-03 |
| David L. Mahoney | Board member (per proxy) bio: Private Investor | DEF 14A, 2026-04-17 |
| G. Leonard Baker, Jr. | director | 8-K, 2026-05-28 |
What Corcept Therapeutics Inc does
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 109.4 million (as of October 22, 2026) | 10-Q, November 3, 2026 |
|---|---|---|
| Public float | $6.1B (as of June 30, 2025) | 10-K, February 24, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 3, 2026 |
| Latest proxy statement | Meeting April 17, 2026 (filed April 17, 2026) | DEF 14A, April 17, 2026 |
| Auditor | Ernst & Young LLP (San Mateo, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | Sale | 8,333 | $674K | Form 4, November 4, 2026 |
| October 15, 2026 | James N. Wilson Director | Sale | 10,000 | $1.1M | Form 4, October 16, 2026 |
| October 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | Sale | 8,333 | $967K | Form 4, October 5, 2026 |
| October 2, 2026 | Joseph Douglas Lyon See Remarks | Sale | 10,000 | $1.2M | Form 4, October 5, 2026 |
| October 2, 2026 | Sean Maduck See Remarks | Sale | 25,000 | $2.9M | Form 4, October 5, 2026 |
| September 16, 2026 | Roberto Wandenkolk Vieira President, Oncology | Sale | 296 | $30K | Form 4, September 18, 2026 |
| September 15, 2026 | James N. Wilson Director | Sale | 10,000 | $1.1M | Form 4, September 16, 2026 |
| September 14, 2026 | Joseph Douglas Lyon See Remarks | Sale | 10,000 | $1.1M | Form 4, September 16, 2026 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-17
- Item 8.01 Other events
- 8-K filed 2026-06-03
- Item 8.01 Other events
- 8-K filed 2026-05-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-25
- Item 8.01 Other events
- 8-K filed 2026-02-24
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-19
- Item 8.01 Other events
Frequently asked questions about Corcept Therapeutics Inc
- What does Corcept Therapeutics Inc do?
- In its own words, from Item 1 of its 10-K: "We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol."
- What is Corcept Therapeutics Inc's revenue?
- $761M for the fiscal year ending December 31, 2025, from its 10-K filed February 24, 2026.
- Is Corcept Therapeutics Inc profitable?
- Corcept Therapeutics Inc reported net income of $99.7M for the fiscal year ending December 31, 2025.
- How many employees does Corcept Therapeutics Inc have?
- About 730 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Corcept Therapeutics Inc?
- Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer, as named in a 8-K filed November 3, 2026.
- Who is the CFO of Corcept Therapeutics Inc?
- Atabak Mokari, Chief Financial Officer, as named in a 4 filed September 3, 2026.
- Where is Corcept Therapeutics Inc headquartered?
- Redwood City, CA.
- What is Corcept Therapeutics Inc's stock ticker?
- CORT on Nasdaq.
- What industry is Corcept Therapeutics Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Corcept Therapeutics Inc's website?
- corcept.com.
- When does Corcept Therapeutics Inc report earnings next?
- February 8, 2027. Source: estimate_8k_pattern.
- Is Corcept Therapeutics Inc a public company?
- Yes. Corcept Therapeutics Inc files with the SEC under CIK 0001088856 and trades as CORT.
- Who audits Corcept Therapeutics Inc?
- Ernst & Young LLP, San Mateo, California, as named in its latest annual report (10-K).
- How many shares of Corcept Therapeutics Inc are outstanding?
- 109.4 million shares as of October 22, 2026, from its 10-Q filed November 3, 2026.
- What is Corcept Therapeutics Inc's public float?
- $6.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 24, 2026.
- How many business segments does Corcept Therapeutics Inc report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 3, 2026.
- When is Corcept Therapeutics Inc's annual shareholder meeting?
- April 17, 2026, per its proxy statement (DEF 14A) filed April 17, 2026.
- Have Corcept Therapeutics Inc insiders traded stock recently?
- Since December 2, 2025, officers and directors reported 44 open-market sales worth about $88.4M and 1 purchase worth about $3.3M on Forms 4 and 5. The most recent: Roberto Wandenkolk Vieira (President, Oncology) sold 8,333 shares on November 2, 2026.